Framework, Organization, and Applications of the Simcyp Population-Based Simulator to Support New Drug Development
暂无分享,去创建一个
[1] M. Sculpher,et al. Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.
[2] Casopitant: In Vitro Data and SimCyp Simulation to Predict In Vivo Metabolic Interactions Involving Cytochrome P450 3A4 , 2011, Drug Metabolism and Disposition.
[3] G. Tucker,et al. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. , 1986, British journal of clinical pharmacology.
[4] A Rostami-Hodjegan,et al. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. , 2010, Current drug metabolism.
[5] M. Mugford,et al. Genetic health technology and economic evaluation , 2006, Applied health economics and health policy.
[6] A J Atkinson,et al. Systems Clinical Pharmacology , 2010, Clinical pharmacology and therapeutics.
[7] S. Golder,et al. Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment , 2012, PharmacoEconomics.
[8] K. G. Jensen,et al. Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[9] M. Jamei,et al. Modeling and predicting drug pharmacokinetics in patients with renal impairment , 2011, Expert review of clinical pharmacology.
[10] N. Waters,et al. Integrated in Vitro Analysis for the in Vivo Prediction of Cytochrome P450-Mediated Drug-Drug Interactions , 2008, Drug Metabolism and Disposition.
[11] L. Wienkers,et al. Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation , 2010, Drug Metabolism and Disposition.
[12] M. Monshouwer,et al. Determination of Time-Dependent Inactivation of CYP3A4 in Cryopreserved Human Hepatocytes and Assessment of Human Drug-Drug Interactions , 2011, Drug Metabolism and Disposition.
[13] Kazuya Maeda,et al. Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.
[14] S. Vegter,et al. Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature , 2010 .
[15] T. Arafat,et al. Effect of Microgravity on the Pharmacokinetics of Ibuprofen in Humans , 2011, Journal of clinical pharmacology.
[16] T O Jefferson,et al. Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.
[17] J R Powell,et al. Pharmacometrics at FDA: Evolution and Impact on Decisions , 2007, Clinical pharmacology and therapeutics.
[18] Granville Sewell,et al. The numerical solution of ordinary and partial differential equations , 2005 .
[19] B. Lum,et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition , 2007, European Journal of Clinical Pharmacology.
[20] A. Gelman,et al. Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .
[21] James E. Bennett,et al. The Bayesian modeling of covariates for population pharmacokinetic models , 1996 .
[22] A E Ades,et al. Use of evidence in economic decision models: practical issues and methodological challenges. , 2007, Health economics.
[23] J. Shin,et al. Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin , 2008, Clinical pharmacology and therapeutics.
[24] B. O'brien,et al. Economic Considerations for Health Insurance Coverage of Emerging Genetic Tests , 2003, Public Health Genomics.
[25] Yuan Chen,et al. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies , 2012, Biopharmaceutics & drug disposition.
[26] Masoud Jamei,et al. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[27] Katherine Payne,et al. The Appropriate Elicitation of Expert Opinion in Economic Models , 2011, PharmacoEconomics.
[28] M. H. Ensom,et al. Pharmacogenetics , 2001, Clinical pharmacokinetics.
[29] D. Cortese,et al. Severe hypoxemia and liver disease. , 1989, The American review of respiratory disease.
[30] M. Jamei,et al. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.
[31] C. Flowers,et al. The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics , 2012, PharmacoEconomics.
[32] Robert J Riley,et al. Time-dependent CYP inhibition , 2007, Expert opinion on drug metabolism & toxicology.
[33] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[34] W. Newman,et al. Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom , 2010, British Journal of Cancer.
[35] Saeed Rezaee,et al. Incorporating In Vitro Information on Drug Metabolism Into Clinical Trial Simulations to Assess the Effect of CYP2D6 Polymorphism on Pharmacokinetics and Pharmacodynamics: Dextromethorphan as a Model Application , 2007, Journal of clinical pharmacology.
[36] John C Lipscomb,et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.
[37] I Zineh,et al. Clinical Pharmacology and the Catalysis of Regulatory Science: Opportunities for the Advancement of Drug Development and Evaluation , 2013, Clinical pharmacology and therapeutics.
[38] L. Wienkers,et al. Predicting in vivo drug interactions from in vitro drug discovery data , 2005, Nature Reviews Drug Discovery.
[39] C. Mathias. Effect of food intake on cardiovascular control in patients with impaired autonomic function , 1990, Journal of Neuroscience Methods.
[40] Lewis B. Sheiner,et al. The NONMEM System , 1980 .
[41] Amin Rostami-Hodjegan,et al. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. , 2009, British journal of clinical pharmacology.
[42] L. Berezhkovskiy,et al. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. , 2004, Journal of pharmaceutical sciences.
[43] Maarten J. Postma,et al. Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes , 2012, PharmacoEconomics.
[44] Katrina Armstrong,et al. Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.
[45] Elizabeth Foot,et al. Pharmacogenetics--pivotal to the future of the biopharmaceutical industry. , 2010, Drug discovery today.
[46] Anthony O'Hagan,et al. Review of Statistical Methods for Analysing Healthcare Resources and Costs , 2010, Health economics.
[47] C. Wolf,et al. Science, medicine, and the future: Pharmacogenetics. , 2000, BMJ.
[48] Alex Phipps,et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. , 2008, British journal of clinical pharmacology.
[49] W Ewy,et al. Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.
[50] T. Nolin,et al. Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport , 2008, Clinical pharmacology and therapeutics.
[51] M. Wilson,et al. Regulation of intestinal blood flow. , 2000, The Journal of surgical research.
[52] F Kesisoglou,et al. Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling , 2009, Xenobiotica; the fate of foreign compounds in biological systems.
[53] Kathryn A Phillips,et al. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. , 2004, Pharmacogenomics.
[54] Malcolm Rowland,et al. Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.
[55] K Rowland-Yeo,et al. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[56] Maurice Dickins,et al. Maraviroc: in vitro assessment of drug-drug interaction potential. , 2008, British journal of clinical pharmacology.
[57] Thomas R Fleming. Objective response rate as a surrogate end point: a commentary. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] D. Rock,et al. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements , 2008 .
[59] S. Duffy,et al. Are adverse effects incorporated in economic models? An initial review of current practice. , 2009, Health technology assessment.
[60] Anthony J Culyer,et al. National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.
[61] G. Tucker,et al. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[62] Karl Claxton,et al. Exploring Uncertainty in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.
[63] L B Sheiner,et al. Estimating population kinetics. , 1982, Critical reviews in biomedical engineering.
[64] C. Oo,et al. The Need for Multiple Doses of 400 mg Ketoconazole as a Precipitant Inhibitor of a CYP3A Substrate in an In Vivo Drug‐Drug Interaction Study , 2009, Journal of clinical pharmacology.
[65] Amin Rostami-Hodjegan,et al. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.
[66] J. Lipscomb,et al. Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling , 2008, Drug Metabolism and Disposition.
[67] I. Bruce,et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription , 2007, Journal of clinical pharmacy and therapeutics.
[68] G. Tucker,et al. Measurement of the renal clearance of drugs. , 1981, British journal of clinical pharmacology.
[69] G Levy,et al. Effect of plasma protein binding on renal clearance of drugs. , 1980, Journal of pharmaceutical sciences.
[70] M. Jamei,et al. Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients , 2011, Clinical pharmacokinetics.
[71] U. Klotz,et al. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. , 1975, The Journal of clinical investigation.
[72] G. Skiles,et al. Simulation of Clinical Drug-Drug Interactions from Hepatocyte CYP3A4 Induction Data and Its Potential Utility in Trial Designs , 2011, Drug Metabolism and Disposition.
[73] Marie Davidian,et al. Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[74] A. Beresford,et al. The emerging importance of predictive ADME simulation in drug discovery. , 2002, Drug discovery today.
[75] F. Trevisani,et al. The hemodynamic status of preascitic cirrhosis: An evaluation under steady‐state conditions and after postural change , 1992, Hepatology.
[76] Sebastian Polak,et al. Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.
[77] B. Scribner,et al. Non-ionic diffusion and the excretion of weak acids and bases. , 1958, The American journal of medicine.
[78] M C Weinstein,et al. Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. , 2001, International journal of technology assessment in health care.
[79] Amin Rostami-Hodjegan,et al. Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug–drug interactions: using in vitro data as an aid to assess study power , 2009, Pharmaceutical statistics.
[80] I. Janků. Physiological modelling of renal drug clearance , 2006, European Journal of Clinical Pharmacology.
[81] Eberechukwu Onukwugha,et al. Sensitivity Analysis in Cost-Effectiveness Studies , 2011, PharmacoEconomics.
[82] Goonaseelan Pillai,et al. Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[83] Kathryn A. Phillips,et al. Measuring the value of pharmacogenomics , 2005, Nature Reviews Drug Discovery.
[84] Karl Claxton,et al. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence? , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[85] M. Sculpher,et al. Catalogue of EQ-5D Scores for the United Kingdom , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.
[86] Sarah Wordsworth,et al. Eliciting expert opinion for economic models: an applied example. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[87] Daniel Röshammar,et al. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. , 2011, British journal of clinical pharmacology.
[88] E. Burchard,et al. Effects of Genetic Variation in the Novel Organic Cation Transporter, OCTN1, on the Renal Clearance of Gabapentin , 2008, Clinical pharmacology and therapeutics.
[89] G T Tucker,et al. Pharmacokinetic-pharmacogenetic modelling in the detection of polymorphisms in xenobiotic metabolism. , 1990, The Annals of occupational hygiene.
[90] Katherine Payne,et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. , 2011, Pharmacogenomics.
[91] M. Bala,et al. Overview of the pharmacoeconomics of pharmacogenetics. , 2006, Pharmacogenomics.
[92] I. Tomlinson,et al. Molecular testing for somatic cancer mutations: a survey of current and future testing in UK laboratories , 2007, Journal of Clinical Pathology.
[93] G. Tucker,et al. Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies--moving the "goalposts" or changing the "game". , 1994, Journal of pharmaceutical sciences.
[94] Josh J. Carlson,et al. Cost Effectiveness of Pharmacogenomics , 2012, PharmacoEconomics.
[95] Robert J Riley,et al. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[96] Brian Tomlinson,et al. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine , 2008, Pharmacogenetics and genomics.
[97] F Y Bois,et al. An analysis of exposure rate effects for benzene using a physiologically based pharmacokinetic model. , 1992, Regulatory toxicology and pharmacology : RTP.
[98] H. van de Waterbeemd,et al. ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.
[99] Kairui Feng,et al. The Simcyp® Population-based ADME Simulator , 2009 .
[100] M. Jamei,et al. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. , 2010, Toxicology.
[101] B. O'brien,et al. The death of cost-minimization analysis? , 2001, Health economics.
[102] Melvin E. Andersen,et al. What do we Mean by Dose , 1995 .
[103] G. Tucker,et al. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[104] Katherine Payne,et al. Fish and chips all round? Regulation of DNA-based genetic diagnostics. , 2009, Health economics.
[105] T. Lavé,et al. A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics , 2006, Clinical pharmacokinetics.
[106] M. Jamei,et al. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[107] K Rowland-Yeo,et al. Prediction of metabolic drug clearance in humans: In vitro–in vivo extrapolation vs allometric scaling , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[108] L Zhang,et al. Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.
[109] S. Ramsey,et al. Economic analyses of human genetics services: A systematic review , 2005, Genetics in Medicine.
[110] Richard D. Smith,et al. Contingent valuation: (still) on the road to nowhere? , 2009, Health economics.
[111] Amin Rostami-Hodjegan,et al. Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children , 2006, Clinical pharmacokinetics.
[112] G. Tucker,et al. A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance , 2010, Clinical pharmacokinetics.
[113] Amin Rostami-Hodjegan,et al. Changes in liver volume from birth to adulthood: A meta‐analysis , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[114] Kenneth B Wells,et al. Burden of Illness , 1968 .
[115] C. Masimirembwa,et al. In Vitro and in Silico Identification and Characterization of Thiabendazole as a Mechanism-Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions , 2009, Drug Metabolism and Disposition.
[116] Maurice Dickins,et al. Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man , 2008 .
[117] Patrick Poulin,et al. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.
[118] R. Obach,et al. Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism‐based adverse events , 2012, Biopharmaceutics & drug disposition.
[119] A. Rostami-Hodjegan,et al. Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter‐system extrapolation factors , 2011, Biopharmaceutics & drug disposition.
[120] M. Drummond,et al. The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment , 1997, Journal of health services research & policy.
[121] Malcolm Rowland,et al. Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.
[122] G. Tucker,et al. Backtracking booze with Bayes--the retrospective interpretation of blood alcohol data. , 1991, British journal of clinical pharmacology.
[123] Amin Rostami-Hodjegan,et al. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. , 2007, British journal of clinical pharmacology.